Molecular docking and ADMET analysis of hydroxamic acids as HDAC2 inhibitors

Murad Alsawalha1, Srinivasa Rao Bolla2, Naresh Kandakatla3, Venkatesan Srinivasadesikan4,5, Vishnu Priya Veeraraghavan6, Krishna Mohan Surapaneni7,*

1Department of Chemical and Process Engineering Technology, Jubail Industrial College (JIC), P.O. Box 10099, Jubail Industrial City 31961, Kingdom of Saudi Arabia; 2Department of Anatomy, College of Medicine, Imam Abdulrahman Bin Faisal University, P.O.Box 2114, Dammam 31451, Kingdom of Saudi Arabia; 3Department of Chemistry, Sathyabama University, Jeppiaar Nagar, Chennai, 300, Taiwary; 4Department of Sciences and Humanities, Vignan’s Foundation for Science, Technology and Research University, Vadlamudi, 522 213, Guntur, Andhra Pradesh, India; 5Department of Medical Biochemistry, College of Applied Medical Sciences in Jubail (CAMSJ), Imam Abdulrahman Bin Faisal University, Jubail Industrial City 35816, Kingdom; Surapaneni Krishna Mohan - E-mail: skmohan@iau.edu.sa; *Corresponding author

Received April 30, 2019; Accepted May 5, 2019; Published May 30, 2019

DOI: 10.6026/97320630015380

Abstract:
Histone deacetylase (HDAC2) belongs to the hydrolase family and a promising target for cancers. We reported 96 hydroxamic compounds optimized using hydrogen-donors, hydrophobic and electron withdrawing groups followed by molecular docking studies. The optimized compounds show good LibDock score and H-bond interaction in the active site of HDAC2. We selected 20 compounds as the best HDAC2 inhibitors based on the LibDock score, binding energy and hydrogen bonding. ADMET predictions on these compounds show good absorption, BBB penetration and no liver toxicity. We subsequently report four compounds selected as best HDAC2 inhibitors based on the LibDock, binding energy, H-bonding and ADMET properties.

Keywords: ADMET, histone deacetylase 2, hydroxamic acids, molecular docking

Background:
Chromatin structure of histone has two forms such as Histone acetylases (HATs) and Histone deacetylases (HDACs). The acetylation status of histone operated by histone acetylases and histone deacetylases, which are in equilibrium [1]. The main function of HDAC is deacetylation of ε-amino groups of lysine located near the amino terminal of core histone proteins and restore positive charge on lysine residue, which results in tightening of nucleosome structure and gene silencing [2]. HDACs not only deacetylate the histone proteins, but also deacetylate non-histone proteins, such as p53 and GATA-1 [3]. Histone deacetylase protein belongs to the hydrolase family and classified into two classes on the basis of sequence similarity, class I has four isomers of HDAC1-3, and HDAC8 and are related to yeast Rpd3 gene, class II has six isomers of HDAC4-7 and HDAC9-10 and are related to Hda1 and class I and II operated by zinc dependent mechanism [4]. Histone deacetylases (HDACs) control the gene expression and cellular signalling and histone deacetylases 2 (HDAC2) is over expressed in solid tumors including colon cancer, lung cancer, cervical carcinoma, breast cancer, and kidney/cervix cancer and also in Alzheimer’s disease [5-7]. Several natural and synthetic derivatives have been identified to be able to inhibit the activity of the HDACs.
HDAC inhibitors (HDACi) arrest cell growth and leads to differentiation and apoptosis in tumor cells. HDACi can be divided into several structural classes including hydroxamic acids, cyclic peptides, aliphatic acids and benzamides etc. [8-9]. Naturally identified Hydroxamic acid HDAC inhibitor was Trichostatin A (TSA) and SAHA (Suberoylanilide hydroxamic acid or Vorinostat (Zolinza®)) is structurally similar to TSA was first HDAC inhibitor approved for the treatment of refractory cutaneous T-cell lymphoma by Food and Drug Administration (FDA) in October 2006 [10-11]. The compounds with radio sensitizing properties were found to be effective in the clinical application as they are cell specific [12]. Research on the SAHA as HDAC inhibitor for the treatment of hematologic and solid tumors is found to be efficient [13]. Some studies found that HDAC inhibitors can be used for targeting the radio resistant cancers [14]. Trail (Apo2L, TNFSF10) as a mediator tigers the tumor cell death in acute myeloid leukemia [15]. Finding the specific HDACi for the individual HDAC is an important goal since HDACs are found to maintain different biological activities. Drug design is one of the emerging and important fields for drug discovery. The studies help in developing novel structures and potent drug molecules used for the drug therapies [16]. Studies on Uveal melanoma concluded that HDAC inhibitors provoked morphological differentiation which hindered the growth of tumor [17]. SAHA is a low toxic drug that was docked to get 12 different versions by drug modification and was screened. These were evaluated and were found to exhibit more potency and better affinity than the SAHA [18]. In order to develop best class of drugs, the innovative approach for drug designing, is opted by the researchers in recent times [19]. Optimization of HDAC2 inhibitors of hydroxamic acid was reported previously [20-21] and in this study we optimized hydroxamic acid group. Based on our previous QSAR and pharmacophore studies, molecular docking, binding energy and ADMET studies were carried out.

Materials and Methods:

Data set:

Hydroxamic acids were optimized to improve the inhibitory activity towards HDAC2 protein. SAHA was chosen as reference structure to design new set of compounds. Total 96 compounds were designed based on the 3D-QSAR model on hydroxamic acid (Figure 1) [22]. Hydroxamic acid derivatives were optimized with H-bond donors (OH, CH₃, CH=CH₂, Ph), hydrophobic (hydrocarbons - Pyrrole, Furan, Thiophene, Imidazole, Oxazole, Isooxazole, Benzene, Ph-NΟ₂, Ph-COCH₃, Ph-CCl₃, Aniline, Indole, Pyridine and Pyrimidine) and electron withdrawing groups (NO₂, NCH₃, SO₂CH₃, COCl, COOH, COCH₃, COH, Br, Cl and F) were listed in Table 1. Molecular docking analysis performed on these molecules to investigate for better HDAC2 inhibitors. All ligands were sketched using ISIS draw and given as input file in prepare ligand module in Discovery studio (DS). This generated 3D-structures, tautomers, and isomers and filtered the ligands by Lipinski rule of five. After applying the force fields on ligands the structures were minimized for lowest energy.

![Figure 1: Structural requirement for designing potent hydroxamic acids inhibitors](image)

**Protein preparation and docking:**

The crystal structure of HDAC2 (PDB ID: 3MAX) was downloaded from protein database (http://www.rcsb.org/pdb). The protein preparation was carried out in DS by removing water molecules and co-crystallized ligand further applying force filed parameter CHARMM to protein. The receptor binding sites were searched using flood filling algorithm. Docking calculations carried out using LibDock program implemented in discovery studio [23]. The 15 Å site sphere was selected using coordinates in predefined binding site for docking studies. The 500 binding site features, so call “HotSpots” in binding site spheres were determined using a grid placed into the binding site with polar and apolar probes. The conformations of ligands poses were generated using FAST method and then placed into the binding site sphere. The docking poses were pruned and optimized. Final best optimized compounds were selected based on the LibDock score and H-bonds and the results were compared with the SAHA compound.

In 3D molecular docking studies, the candidate compound docked into the target protein and provides a variety of structural information such as hydrogen bonding interaction, electrostatic interaction, and molecular surface complementary and so on. The binding energy of complex calculated using Eq. 1, which gives the better understanding of binding affinity of the docked complex.
Best resulted compounds from molecular docking studies were considered for binding energy calculations. The energies of each inhibitor and HDAC2 were calculated by semi-empirical method PM6 [24]. The energy association of each ligand (ΔE) was estimated by three types of calculations such as (i) single point energy calculations of active site residues of protein and inhibitor complex (E_complex) (ii) energy calculation of chosen active site residue of protein (E_enzyme) and (iii) single point energy calculation on ligand (E_ligand). The PM6 method used in this study because of the size of the complex and also the binding /interaction energies reported using PMx method shows good results [25-30]. The quantum chemical calculations were performed using GAUSSIAN 09 [31].

**ADMET:**

ADMET (Absorption, Distribution, Metabolism, and Excretion): In drug discovery many potential drugs failed in clinical trials or late drug discovery process, due to poor drug like properties and adverse side effects. In the current investigation, all the optimized hydroxamic acid compounds were subjected to ADMET studies to make sure toxicity risks and drug-relevant properties of molecules which are key factors, to determine drug-likeness of lead molecules. ADMET studies were conducted on selected lead compounds using Discovery Studio (Accelrys, San Diego, CA, USA). This module uses six mathematical models, to quantitatively predict properties by a set of rules/keys that specify threshold ADMET characteristics for the chemical structure of the molecules based on the available drug information.

**Table 1:** Different substitutions used in hydroxamic acid derivatives

| Compd No | X      | RI   | Compd No | X     | RI   |
|----------|--------|------|----------|-------|------|
| H1       | N-OH   | NO₃  | H49      | N-OH  | Ph-COOCH₂ |
| H2       | N-OH   | NCH₃ | H50      | N-OH  | Ph-CCl₂  |
| H3       | N-OH   | SO₂CH₃ | H51   | N-OH  | Aniline |
| H4       | N-OH   | COCl | H52      | N-OH  | Indole  |
| H5       | N-OH   | COOH | H53      | N-OH  | Pyridine |
| H6       | N-OH   | COCH₃ | H54    | N-OH  | pyrimidine |
| H7       | N-OH   | COH  | H55      | N-CH₃ | pyrrole |
| H8       | N-OH   | Br   | H56      | N-CH₃ | furan   |
| H9       | N-OH   | Cl   | H57      | N-CH₃ | thioephene |
| H10      | N-OH   | F    | H58      | N-CH₃ | Iimidazole |
| H11      | N-CH₃ | NO₂  | H59      | N-CH₃ | Oxazole |
| H12      | N-CH₃ | NCH₃ | H60      | N-CH₃ | Isoxazole |
| H13      | N-CH₃ | SO₂CH₃ | H61   | N-CH₃ | Benzene |
| H14      | N-CH₃ | COCl | H62      | N-CH₃ | Ph-NO₂ |
| H15      | N-CH₃ | COOR | H63      | N-CH₃ | Ph-COOCH₂ |
| H16      | N-CH₃ | COR  | H64      | N-CH₃ | Ph-CCl₂ |
| H17      | N-CH₃ | COH  | H65      | N-CH₃ | Aniline |
| H18      | N-CH₃ | Br   | H66      | N-CH₃ | Indole |
| H19      | N-CH₃ | Cl   | H67      | N-CH₃ | Pyridine |

H20 N-CH₃ F H68 N-CH₃ pyrimidine
H21 N-CH=CH₂ NO₂ H69 N-CH=CH₂ pyrrole
H22 N-CH=CH₂ NCH₃ H70 N-CH=CH₂ furan
H23 N-CH=CH₂ SO₂CH₃ H71 N-CH=CH₂ thiophene
H24 N-CH=CH₂ COCl H72 N-CH=CH₂ imidazole
H25 N-CH=CH₂ COOR H73 N-CH=CH₂ Oxazole
H26 N-CH=CH₂ COR H74 N-CH=CH₂ Isoxazole
H27 N-CH=CH₂ COH H75 N-CH=CH₂ Benzene
H28 N-CH=CH₂ Br H76 N-CH=CH₂ Ph-NO₂
H29 N-CH=CH₂ Cl H77 N-CH=CH₂ Ph-COOCH₂
H30 N-CH=CH₂ F H78 N-CH=CH₂ Ph-CCl₂
H31 N-Ph NO₂ H79 N-CH=CH₂ Aniline
H32 N-Ph NCH₃ H80 N-CH=CH₂ Indole
H33 N-Ph SO₂CH₃ H81 N-CH=CH₂ Pyridine
H34 N-Ph COCl H82 N-CH=CH₂ pyrimidine
H35 N-Ph COOR H83 N-Ph pyrrole
H36 N-Ph COR H84 N-Ph furan
H37 N-Ph COH H85 N-Ph thiophene
H38 N-Ph Br H86 N-Ph Iimidazole
H39 N-Ph Cl H87 N-Ph Oxazole
H40 N-Ph F H88 N-Ph Isoxazole
H41 N-NO Pyrrole H89 N-Ph Benzene
H42 N-NO Furur H90 N-Ph Ph-NO₂
H43 N-NO thiophene H91 N-Ph Ph-COOCH₂
H44 N-NO Iimidazole H92 N-Ph Ph-CCl₂
H45 N-NO Oxazole H93 N-Ph Aniline
H46 N-NO Isoxazole H94 N-Ph Indole
H47 N-NO Benzene H95 N-Ph Pyridine
H48 N-NO Ph-NO₂ H96 N-Ph pyrimidine

Results and Discussion:

**Molecular docking:**

Molecular docking studies were carried out on 96 designed hydroxamic acids from 3D-QSAR studies. The HDAC2 protein has 3 chains (Chain A, B and C), chain A is selected for docking studies [20, 32]. LibDock score, binding energy and H bonding considers for selection of best HDAC2 inhibitors. SAHA is chosen as reference compound for comparing the docking score of compounds. SAHA has the LibDock score of 126.37 dock score and 4 hydrogen bond interactions with ARG39(2), HIS183, GLY305, GLY154 amino acids and pi-pi interaction with PHE155. About 62 compounds among 96 were shown good docking score than SAHA, top listed 20 compounds with LibDock score and H-bonds were shown in Table 2. Based on molecular docking and H-bond interaction four compounds are selected as best inhibitor of HDAC2 protein. H34 (3-(8-oxo-8-(phenylamino) octanamido) benzoyl chloride) has the LibDock score of 153.22 and three H-bonds with ARG39, HIS146, GLY142 and pi-pi bond with ARG39 shown in Figure 2 (b). It shows oxygen of N-hydroxy group forms H-bonds with HIS146, oxygen of formamide forms H-bonds with GLY142 and ARG39. LibDock score 145.94 for H81 (N-(3-(pyridin-2-yl)phenyl)-N⁵-vinyloctanamide) with three H-bonds with ARG39, TYR308, HIS146 and pi-pi bond with ARG39 shown in Figure 2(c), it shows oxygen of N-hydroxy group forms H-bonds
with HIS146, oxygen of formamide forms H-bond with TYR308 and ARG39. H43 (N1-hydroxy-N8-(3-(thiophen-2-yl) phenyl) octanediamide) has LibDock score of 145.85 and five H-bonds with ARG39, GLN265 (2), HIS145, ASP181, ASP104 and pi-pi bond with ARG39 shown in Figure 2(d), It shows oxygen of N-hydroxyl group forms H-bonds with ASP104, oxygen of formamide forms H-bonds with ASP181, HIS145 and GLN265, thiophene of sulphar forms bonds with ARG39. H30 (N1-(3-fluorophenyl)-N8-vinyl octanediamide) has LibDock score of 143.00 with four H-bonds ARG39 (2), HIS183, GLY305, TRP140 and pi-pi bond with PHE155 shown in Figure 2(e), It shows oxygen of N-hydroxyl group forms H-bonds with ARG39, GLY305 and TRP140 and oxygen of formamide forms H-bond with HIS183. The result shows that N-hydroxyl group, which is an important group and forms interactions with the HDAC2.

Figure 2: Docking poses of top four compounds (a) SAHA (b) (3-(8-oxo-8-(phenylamino)octanamido)benzoyl chloride (H34); (c) N1-(3-(pyridin-2-yl)phenyl)-N8-vinloctanediamide (H81); (d) N1-hydroxy-N8-(3-(thiophen-2-yl)phenyl)octanediamide (H43); (e) N1-(3-fluorophenyl)-N8-vinloctanediamide (H30).
### Table 2: LibDock, Binding energy and H-bond interactions of hydroxamic acids

| Comp | LibDock Score | Binding Energy (Kcal/mol) | H-Bond Monitor | H-Bond distance |
|------|---------------|---------------------------|----------------|-----------------|
| SAHA | 126.37        | -58.25                    | P:ARG39-H21 - L:O9 | 1.80, 2.4, 2.18, 2.46, 1.92 |
| H32  | 162.45        | -18.78                    | P:ARG39-H21 - L:O18 | 2.40, 2.18 |
| H51  | 153.39        | -50.16                    | P:ARG39-H31 - L:O10 | 2.24, 2.12, 2.18, 2.49 |
| H34  | 153.22        | -50.53                    | P:ARG39-H31 - L:O10 | 2.34, 2.2, 2.18, 2.13, 2.00 |
| H36  | 152.17        | -50.9                     | P:ARG39-H32 - L:O9 | 2.31, 1.72, 2.04 |
| H53  | 147.07        | -50.72                    | P:ARG39-H32 - L:O18 | 1.75, 2.12, 2.07, 2.39, 1.88 |
| H81  | 145.94        | -50.08                    | P:ARG39-H32 - L:O10 | 2.36, 2.55, 2.17, 1.90, 1.95 |
| H43  | 145.85        | -45.1                     | P:ARG39-H32 - L:O10 | 2.16, 2.45, 2.40, 2.07, 1.99 |
| H72  | 145.32        | -10.3                     | P:ARG39-H32 - L:O10 | 2.15, 2.02 |
| H67  | 144.66        | -8.4                      | P:ARG39-H31 - L:O9 | 2.37, 1.91 |
| H74  | 144.35        | -5.02                     | P:ARG39-H31 - L:O18 | 1.29, 2.49, 1.92, 1.73 |
| H54  | 144.50        | -55.57                    | P:ARG39-H31 - L:O10 | 1.96, 2.29, 2.12, 1.73 |
| H27  | 144.16        | -40.78                    | P:ARG39-H31 - L:O10 | 2.27, 2.40, 2.45, 2.40, 2.07, 1.95, 2.44, 1.74 |
| H46  | 143.58        | -26.2                     | P:ARG39-H31 - L:O10 | 2.36, 2.46, 1.80, 2.21 |
| H37  | 143.21        | -2.05                     | P:ARG39-H31 - L:O10 | 2.31, 1.21 |
| H30  | 143.05        | -55.76                    | P:ARG39-H31 - L:O10 | 2.16, 2.45, 2.13, 2.18, 1.85 |
| H26  | 142.89        | -26.98                    | P:ARG39-H31 - L:O10 | 2.20, 2.40, 1.97, 1.73 |
| H47  | 142.12        | -56.92                    | P:ARG39-H31 - L:O10 | 2.04, 2.38, 2.05, 1.84 |
| H3   | 141.35        | -20.6                     | P:ARG39-H31 - L:O10 | 1.75, 1.92, 2.09 |
| H69  | 141.30        | -8.06                     | P:ARG39-H31 - L:O10 | 2.17, 1.84 |
| H44  | 141.29        | -57.1                     | P:ARG39-H31 - L:O10 | 2.18, 2.18, 2.21, 1.82, 2.08 |
Binding Energy calculation:

Binding energy calculations were performed on the best 20 Compounds which have good docking score and H-bond interaction and results are listed in Table 2. In order to compare the obtained Binding energy (ΔE), calculations also performed on active HDAC2 inhibitors (SAHA). Table 2 shows the binding energy calculation (PM6) of HDAC2-inhibitor complexes. The binding energy of active HDAC2 inhibitors SAHA is -33.25 kcal/mol, and the binding energy of selected four compounds as (3-(8-oxo-8-(phenylamino) octanamido)benzoyl chloride (H34) (-39.53 kcal/mol), N1-(3-pyridin-2-yl)phenyl)-N8-vinloctanediame (H81) (-56.08 kcal/mol), N1-hyrox-N8-(3-thiophen-2-yl)phenyl octanediame (H43) (-43.21 kcal/mol), N1-(3-fluorophenyl)-N8-vinloctanediame) (-35.76 kcal/mol), it shows these compounds have smaller binding energy than active HDAC2 inhibitors and were suggesting an inhibitors of HDAC2. The compounds, which are having hydrogen bond interactions with ARG, HIS, TYR active residues shows smaller binding energies. This implies that the active site residues ARG, HIS, TYR are become more favourable to the binding of HDAC2 inhibitors.

ADMET:

ADMET predictions were carried out to evaluate drug likeness of top 20 selected compounds and the properties were reported in Table 3 together with biplot Figure 3. The pharmacokinetic profiles of selected compounds were predicted by means of six pre-calculated ADMET model provided by Discovery studio. Figure 3 bi plot shows two analogous 95% and 99% confidence ellipse corresponding to HIA and BBB models. PSA have inverse relationship with human intestinal absorption and thus cell wall permeability. The log P used to estimate the lipophilicity, thus the information of H-bonding characteristics as obtained by calculating PSA could be taken into consideration along with logP calculation. The model with descriptors AlogP98 and PSA 2D with a bi-plot comprising 95% and 99% confidence ellipses was considered for the accurate prediction for the cell permeability of compounds. Selected 20 compounds had a good adsorption prediction for metabolism. In toxicity evaluation except H32 all compounds displayed CYP2D6 inhibiting and hepatotoxicity, suggesting that these compounds have no toxicity in the liver. Blood brain barrier (BBB) penetration showed that 10 compounds have good penetration; 8 compounds have low penetration and 2 compounds have undefined penetration; 10 compounds may suitable for central nerve system therapy. Four compounds (3-(8-oxo-8-(phenylamino)octanamido)benzoyl chloride (H34); N1-(3-pyridin-2-yl)phenyl)-N8-vinloctanediame (H81); N1-hyrox-N8-(3-thiophen-2-yl)phenyl octanediame (H43); N1-(3-fluorophenyl)-N8-vinloctanediame) (H30) were selected as potential compounds based on the LibDock, binding energy, H bonding and ADMET properties.

Table 3: ADMET prediction of top 20 optimized compounds

| Compound | Absorption | BBB Level | CYP2D6 | Hepatotoxicity |
|----------|------------|-----------|--------|----------------|
| Compound 3 | 0 | 1 | 1 | 0.509 |
| Compound 26 | 0 | 3 | 1 | 0.536 |
| Compound 27 | 0 | 3 | 1 | 0.509 |
| Compound 30 | 0 | 2 | 1 | 0.476 |
| Compound 32 | 0 | 2 | 0 | 0.582 |
| Compound 34 | 0 | 2 | 1 | 0.701 |
| Compound 36 | 0 | 2 | 1 | 0.688 |
| Compound 37 | 0 | 2 | 1 | 0.642 |
| Compound 43 | 0 | 2 | 1 | 0.602 |
| Compound 44 | 0 | 3 | 1 | 0.49 |
| Compound 46 | 0 | 3 | 1 | 0.437 |
| Compound 47 | 0 | 2 | 1 | 0.662 |
| Compound 51 | 0 | 4 | 1 | 0.682 |
| Compound 53 | 0 | 3 | 1 | 0.682 |
| Compound 54 | 0 | 3 | 1 | 0.655 |
| Compound 67 | 0 | 2 | 1 | 0.509 |
| Compound 69 | 0 | 2 | 1 | 0.596 |
| Compound 72 | 0 | 3 | 1 | 0.503 |
| Compound 74 | 0 | 3 | 1 | 0.443 |
| Compound 81 | 0 | 2 | 1 | 0.649 |

*Absorption: good absorption = 0; moderate absorption = 1; low absorption = 2; BBB level (blood brain barrier): very high penetration = 0; high penetration = 1; medium penetration = 2; low penetration = 3; undefined penetration = 4. CYP2D6: noninhibitor = 0, inhibitor = 1. Hepatotoxicity: noninhibitor = 0, inhibitor = 1.

Conclusion:

It is of interest to identify better inhibitors for HDAC2. Here, we report the binding of 4 HDAC2 inhibitors with optimal LibDock
score, binding energy and hydrogen-bonds. It is further noted by ADMET analysis that these compounds have good absorption, less toxic in the human liver and BBB penetration and may therefore suggest as HDAC2 inhibitors.

References:
[1] Monneret C, Eur J Med Chem. 2005 40: 1 [PMID: 15642405].
[2] Mai A et al. J Med Chem. 2002 45: 1778 [PMID: 11960489].
[3] Juan LJ et al. J Biol Chem. 2000 275: 20436 [PMID: 10777477].
[4] Bielaukas AV & Pfum MK, Chem Soc 2008 37: 1402 [PMID: 18568166].
[5] Gregoretti IV et al. Journal of Molecular Biology. 2004 338: 17 [PMID: 15619633].
[6] Kramer OH, Trends in Pharmacological Sciences. 2009 30: 647 [PMID: 19892411].
[7] Johnstone RW. Nature Reviews Drug Discovery. 2002 1: 287 [PMID: 12120280].
[8] Kilgore M et al. Neuro psycho pharmacology. 2010 35: 870 [PMID: 18663490].
[9] Kapustin GV et al. Org Lett. 2003 5: 3053 [PMID: 12916979].
[10] Blum KA et al. Br J Haematol. 2009 147: 507 [PMID: 19747365].
[11] Marks PA & Breslow R. Nature Biotechnology 2007 25: 84 [PMID: 17211407].
[12] Jung M et al. Radiat. Res. 2005 163: 488 [PMID: 15850409].
[13] Kelly WK & Marks PA, Nature Clinical Practice Oncology. 2005 2: 150 [PMID: 16264908].
[14] Zhang Y et al. Radiation Research. 2004 161: 667 [PMID: 15161353].
[15] Nebbioso A et al. Nature Medicine. 2005 11: 77 [PMID: 15619633].
[16] Melagraki G et al. Mol Divers. 2009 13: 301 [PMID: 19205914].
[17] Landreville S et al. Clin Cancer Res. 2012 18: 408 [PMID: 22038994].
[18] Tambunan USF, BMC Bioinformatics. 2011 12: S23 [PMID: 22373132].
[19] Mills JJS & Showell GA, Expert Opinion on Investigational Drugs. 2004 13: 1149 [PMID: 15330746].
[20] Walkinshaw DR & Yang XJ. Curr Oncol. 2008 15: 237 [PMID: 19008999].
[21] Naresh K et al. Bangladesh J Pharmacol. 2013 8: 328.
[22] Naresh K et al. International conference on Engineering & physical sciences 2015
[23] Diller DJ & Merz ML. Proteins: Structure, Function, and Genetics. 2001 43: 113 [PMID: 11276081].
[24] Stewart JJP, J Mol Model. 2007 13: 1173 [PMID: 17828561].
[25] Araújo PMM et al. Chem Phys Lett. 2014 591: 273.
[26] Anisimov VM & Cavasotto CN. J Comput Chem. 2011: 1 [PMID: 21484840].
[27] Dubey KD & Ojha RP, J Biol Phys. 2011 37: 69 [PMID: 22210962].
[28] Nunthaboot N et al. J Phys Chem B. 2008 112: 15837.
[29] Xiong YZ & Chen PY. J Mol Model. 2008 14: 1083 [PMID: 18663490].
[30] Pinto da Silva L et al. Chem Phys Lett. 2012 543: 137.
[31] Frisch MJ et al. (2009) Gaussian, Inc., Wallingford CT
[32] Naresh K & Geetha R. Advances in Bioinformatics. 2014 p812148 [PMID: 25525429].

License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License
